Pemetrexed Disodium Injection 100mg

Pemetrexed Disodium Injection 100mg: What the Published Guidance Says

Cytotoxic and targeted agents spanning the taxane, antifolate and EGFR-tyrosine-kinase-inhibitor classes, supplied with the analytical and stability documentation oncology procurement requires.

Before Pemetrexed Disodium Injection 100mg is quoted, we confirm the monograph, the strength on the artwork and the release testing required by your market — the points summarised here.

• 2025 extended access to checkpoint inhibitors Pembrolizumab was added to the Model List as first-line monotherapy for metastatic cervical cancer, metastatic colorectal cancer and metastatic non-small cell lung cancer, with atezolizumab and cemiplimab as therapeutic alternatives for the lung indication. WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)
• EGFR tyrosine-kinase inhibitors and their toxicity profile In its review of non-small cell lung cancer, the WHO Expert Committee recorded that EGFR tyrosine-kinase inhibitors are generally well tolerated, with diarrhoea occurring in more than 60% of patients treated, characteristic dermatological toxicity and rash across the class, and potential hepatic toxicity. Rare but severe gastrointestinal toxicity, including perforation, was noted particularly with erlotinib. WHO EML Expert Committee — Non-small cell lung cancer review
• Paclitaxel: premedication is part of the product's use The same review records that paclitaxel is associated with a high incidence of neutropenia, frequently severe, and can cause hypersensitivity reactions in up to 30% of patients, so premedication is required to reduce that risk. Alopecia is described as universal and peripheral neuropathy common, both reversible. WHO EML Expert Committee — Non-small cell lung cancer review

Each point above is reproduced because it has a practical consequence for Pemetrexed Disodium Injection 100mg: the strength you can register, the pack you can release, or the wording permitted on the label. Your national prescribing information always takes precedence.

Pemetrexed Disodium Injection 100mg — Supply Parameters

The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Paclitaxel Albumin-Bound 100mg/20mL, Sunitinib Malate 12.5mg Capsules, Afatinib Dimaleate 40mg Tablets, Erlotinib Hydrochloride 150mg Tablets, Gefitinib Tablets 250mg.

Quality Control, Pharmacopoeial Standards & Documentation

Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.

Release testing for Pemetrexed Disodium Injection 100mg follows the monograph you nominate — USP, EP, BP or CP. If the presentation is not covered by a monograph, the specification is frozen in writing with your quality team before the batch is manufactured.

Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.

A typical release panel for this presentation covers:

• Testing for uniformity of dosage units
• Testing for water content and pH where applicable
• Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
• Testing for microbial limits and preservative efficacy (multi-dose presentations)
• Testing for heavy metals and elemental impurities
• Testing for packaging integrity and seal testing

COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.

Packaging, Labelling & Export

• Pack size: 100mg sterile type I glass vial with rubber stopper and aluminum flip-off seal. Non-standard pack sizes can be quoted against your artwork.
• Storage: Store below 25°C, protected from light. Do not freeze. Keep vial in outer carton until use. Reconstituted and diluted solutions should be used within 24 hours if refrigerated (2–8°C), or within 12 hours at room temperature (below 25°C)..
• Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
• Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
• Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.

Registration, Dossier & Tender Support

The legal manufacturer named on every document for Pemetrexed Disodium Injection 100mg is Sinophare Bio-technology Co., Ltd., DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. The same entity appears on the GMP certificate and on the dossier submitted to your regulator.

• Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
• Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
• Batch manufacturing and packaging records released for inspection on request during supplier audits.
• Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
• CTD dossier modules 1–5 in editable and PDF form, with the finished-product and API sections cross-referenced.

Pemetrexed Disodium Injection 100mg is presented here against cancer medicines reviewed for the WHO Model List. Inclusion in an essential-medicines list does not authorise sale in any particular country — the marketing authorisation for that market is a separate step.

Related Oncology Products

• Paclitaxel Albumin-Bound 100mg/20mL — 100mg
• Sunitinib Malate 12.5mg Capsules — 12.5mg
• Afatinib Dimaleate 40mg Tablets — 40mg
• Erlotinib Hydrochloride 150mg Tablets — 150mg
• Gefitinib Tablets 250mg — 250mg

Browse the full Oncology range; all Injectables; the complete product catalogue.